Malaria Cured In Hours - Red Cross Study Uganda 2012: What They Don't Want You To Know (Connecting the Dots: American Red Cross, Malaria, Novartis & Soros Funding, All Networking)
Novartis
- Malaria
https://www.novartis.com/diseases/malaria
Malaria
Novartis has been committed to the fight against malaria for
more than two decades. In 1999 we launched the first fixed-dose Artemisinin-based
combination therapy (ACT) and in 2009 the first dispersible pediatric ACT
developed in partnership with Medicines for Malaria Venture (MMV).
Today we are working on the development of the next generation of antimalarials
to address the ever-growing threat of parasite resistance.
Drug
discovery efforts at the Novartis Institute for Tropical Diseases (NITD) have
delivered an industry-leading pipeline of drug candidates to address the
emerging threat of resistance. Two antimalarials in development, KAF156
(ganaplacide) and KAE609 (cipargamin), offer new mechanisms of action against
the disease and have the potential to offer simplified therapeutic regimens
over current treatments.
Ganaplacide
demonstrated activity against both vivax and falciparum malaria, including
artemisinin-resistant parasites. It is being developed as a combination with a
new formulation of lumefantrine. In November 2022, Novartis and Medicines for
Malaria Venture (MMV) announced the decision to progress the combination into
Phase 3 development in 2023. The trial will be conducted in collaboration with
the WANECAM 2 consortium, and will include partner clinical sites in Burkina
Faso, Mali, Gabon and Niger as well as other sites in sub-Saharan Africa.
Novartis leads the development of ganaplacide with scientific and financial
support from MMV in collaboration with the Bill & Melinda
Gates Foundation.
The
development of cipargamin is led by Novartis with financial support from
Wellcome. The clinical trials for ganaplacide are conducted as part of the
WANECAM2 consortium, while trials for cipargamin and our infant formulation are
part of the PAMAfrica research consortium led by MMV. Both trials are funded by
the European and Developing Countries Clinical Trials Partnership (EDCTP).
In
2020, Novartis advanced another novel malaria therapy, INE963, a fast acting
long-lasting antimalarial with an entirely new mechanism of action. INE963 is
in early clinical trials. It is developed in collaboration with MMV and
received the organization’s “Project of the Year” award in 2020.
Connecting
the Dots:
Novartis
Corporation is a U.S. subsidiary of Novartis AG and a
member of the Pharmaceutical Research and Manufacturers of America.
Akin,
Gump, Strauss, Hauer & Feld, LLP is the lobby firm for the Novartis
Corporation and the Pharmaceutical Research and Manufacturers
of America.
Vernon E. Jordan
Jr. is a senior counsel for Akin, Gump, Strauss, Hauer
& Feld, LLP and an honorary trustee at the Brookings
Institution (think tank).
Foundation to Promote Open Society was a funder
for the Brookings Institution (think tank).
George Soros was the
chairman for the Foundation to Promote Open Society.
Mark B. McClellan was a senior
fellow at the Brookings Institution (think tank) and a commissioner
for the U.S. Food and Drug Administration (FDA).
Ann
M. Fudge is a trustee at the Brookings
Institution (think tank) and a director at Novartis AG.
Suzanne Nora Johnson is a trustee
at the Brookings Institution (think tank) and was a governor for
the American Red Cross.
Foundation to Promote Open Society was a funder for
the Brookings Institution (think tank) and Refugees International.
George Soros was the chairman for
the Foundation to Promote Open Society and is a director
emeritus for Refugees International.
Steven E. Carr was
a director at Refugees International and a governor for
the American Red Cross.
Carol Ann Haake was
a director at Refugees International and a governor for
the American Red Cross.
Michael W.
Hawkins is a director at Refugees International and
was a governor for the American Red Cross.
George Soros is a director emeritus
for Refugees International and was the chairman for the Foundation
to Promote Open Society.
Foundation to Promote Open Society was a funder for
Refugees International and the Brookings Institution (think tank).
Cameron F. Kerry is
a fellow at the Brookings Institution (think tank), John F.
Kerry’s brother and a senior counsel at Sidley Austin LLP.
Barack Obama was
an intern at Sidley Austin LLP.
Michelle Obama was
a lawyer at Sidley Austin LLP.
Mark A. Angelson was
a partner at Sidley Austin LLP and is a trustee at the Institute
of International Education.
Kyle House Group is
the lobby firm for the Institute of International Education
and Malaria No More.
Gabrielle
Fitzgerald is a founding board member for Malaria No More
and was the director of program advocacy for the Bill & Melinda
Gates Foundation.
Bill
& Melinda Gates Foundation was a funder for the Brookings
Institution (think tank).
Mark B. McClellan was
a senior fellow at the Brookings Institution (think tank) and
a commissioner for the U.S. Food and Drug Administration (FDA).
Ann M. Fudge is a
trustee at the Brookings Institution (think tank) and a
director at Novartis AG.
Suzanne Nora
Johnson is a trustee at the Brookings Institution (think tank)
and was a governor for the American Red Cross.
Foundation to Promote Open Society was a funder
for the Brookings Institution (think tank).
George Soros was the chairman for
the Foundation to Promote Open Society.
Resources:
Past Research
Rick
Warren Hopes to Expand Ministry in Africa (Past
Research on Malaria)
THURSDAY,
AUGUST 21, 2014
https://thesteadydrip.blogspot.com/2014/08/rick-warren-hopes-to-expand-ministry-in.html
Novartis
Seeks COVID-19 Antiviral Candidate Authorization (Past
Research on Novartis)
SUNDAY,
APRIL 24, 2022
https://thesteadydrip.blogspot.com/2022/04/novartis-seeks-covid-19-antiviral.html
Be
Careful That Your Donations Don’t End Up In The Wrong Hands (Past Research on the American Red Cross)
https://thesteadydrip.blogspot.com/2022/10/be-careful-that-your-donations-dont-end.html
Hours
After John Kerry Demands Green Transition Accelerated – His Emissions Closet
Swings Wide Open (Connecting the Dots: Cameron Kerry, John Kerry, Teresa Heinz
Kerry, Soros, the Climate Reality Project, the Brookings Institution (think
tank), the EPA and onto the FDA, Pfizer & Johnson & Johnson. It’s the
Network That Never Ends. One Project (Climate Change) Just bleeds into the Next
(Covid Project)) (Past Research on Cameron Kerry
& Sidley Austin LLP)
THURSDAY,
JULY 21, 2022
https://thesteadydrip.blogspot.com/2022/07/hours-after-john-kerry-demands-green.html
THE
SORO’S NETWORK IS JUST PLAIN EVIL! (Past Research
on the Bill & Melinda Gates Foundation)
MONDAY,
DECEMBER 30, 2013
No comments:
Post a Comment